QQQ   423.56 (-0.54%)
AAPL   166.76 (-0.74%)
MSFT   406.11 (-1.39%)
META   504.49 (+2.09%)
GOOGL   156.47 (+0.64%)
AMZN   179.02 (-1.25%)
TSLA   149.66 (-3.72%)
NVDA   844.97 (+0.55%)
AMD   153.75 (-0.18%)
NIO   4.02 (+2.81%)
BABA   68.99 (+0.25%)
T   16.22 (+0.62%)
F   12.02 (-0.17%)
MU   112.69 (-3.13%)
GE   154.24 (-0.92%)
CGC   7.98 (+22.96%)
DIS   112.94 (+0.00%)
AMC   2.89 (-3.02%)
PFE   25.29 (-0.51%)
PYPL   62.09 (-1.85%)
XOM   118.39 (-0.20%)
QQQ   423.56 (-0.54%)
AAPL   166.76 (-0.74%)
MSFT   406.11 (-1.39%)
META   504.49 (+2.09%)
GOOGL   156.47 (+0.64%)
AMZN   179.02 (-1.25%)
TSLA   149.66 (-3.72%)
NVDA   844.97 (+0.55%)
AMD   153.75 (-0.18%)
NIO   4.02 (+2.81%)
BABA   68.99 (+0.25%)
T   16.22 (+0.62%)
F   12.02 (-0.17%)
MU   112.69 (-3.13%)
GE   154.24 (-0.92%)
CGC   7.98 (+22.96%)
DIS   112.94 (+0.00%)
AMC   2.89 (-3.02%)
PFE   25.29 (-0.51%)
PYPL   62.09 (-1.85%)
XOM   118.39 (-0.20%)
QQQ   423.56 (-0.54%)
AAPL   166.76 (-0.74%)
MSFT   406.11 (-1.39%)
META   504.49 (+2.09%)
GOOGL   156.47 (+0.64%)
AMZN   179.02 (-1.25%)
TSLA   149.66 (-3.72%)
NVDA   844.97 (+0.55%)
AMD   153.75 (-0.18%)
NIO   4.02 (+2.81%)
BABA   68.99 (+0.25%)
T   16.22 (+0.62%)
F   12.02 (-0.17%)
MU   112.69 (-3.13%)
GE   154.24 (-0.92%)
CGC   7.98 (+22.96%)
DIS   112.94 (+0.00%)
AMC   2.89 (-3.02%)
PFE   25.29 (-0.51%)
PYPL   62.09 (-1.85%)
XOM   118.39 (-0.20%)
QQQ   423.56 (-0.54%)
AAPL   166.76 (-0.74%)
MSFT   406.11 (-1.39%)
META   504.49 (+2.09%)
GOOGL   156.47 (+0.64%)
AMZN   179.02 (-1.25%)
TSLA   149.66 (-3.72%)
NVDA   844.97 (+0.55%)
AMD   153.75 (-0.18%)
NIO   4.02 (+2.81%)
BABA   68.99 (+0.25%)
T   16.22 (+0.62%)
F   12.02 (-0.17%)
MU   112.69 (-3.13%)
GE   154.24 (-0.92%)
CGC   7.98 (+22.96%)
DIS   112.94 (+0.00%)
AMC   2.89 (-3.02%)
PFE   25.29 (-0.51%)
PYPL   62.09 (-1.85%)
XOM   118.39 (-0.20%)
Free Trial
NASDAQ:NRBO

NeuroBo Pharmaceuticals (NRBO) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)
Free NRBO Stock Alerts
$3.45
-0.01 (-0.29%)
(As of 01:07 PM ET)
Compare
Today's Range
$3.35
▼
$3.59
50-Day Range
$3.40
▼
$6.52
52-Week Range
$2.89
▼
$6.75
Volume
18,876 shs
Average Volume
1.12 million shs
Market Capitalization
$16.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media

NeuroBo Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.93% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.62mentions of NeuroBo Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.00) to ($1.90) Per Share

Overall MarketRank™

New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.03 out of 5 stars

See Top Rated MarketRank™ Stocks Here
NRBO stock logo

About NeuroBo Pharmaceuticals Stock (NASDAQ:NRBO)

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

NRBO Stock Price History

NRBO Stock News Headlines

April 17, 2024 | finance.yahoo.com
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
April 17, 2024 | prnewswire.com
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
April 18, 2024 | Gold Safe Exchange (Ad)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
April 5, 2024 | morningstar.com
NeuroBo Pharmaceuticals Inc NRBO
April 1, 2024 | prnewswire.com
NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
March 28, 2024 | finanznachrichten.de
NeuroBo Pharmaceuticals, Inc.: NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
March 28, 2024 | prnewswire.com
NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
March 13, 2024 | markets.businessinsider.com
NeuroBo Pharma Gets Approval To Proceed With Phase 2a Trial For DA-1241 To Treat MASH; Stock Up 8%
April 18, 2024 | Gold Safe Exchange (Ad)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
March 13, 2024 | prnewswire.com
NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
March 4, 2024 | finanznachrichten.de
NeuroBo Pharmaceuticals, Inc.: NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer
March 4, 2024 | msn.com
NeuroBo Pharmaceuticals appoints Marshall Woodworth as CFO
March 4, 2024 | markets.businessinsider.com
NeuroBo Pharmaceuticals Confirms Marshall Woodworth As New CFO
March 4, 2024 | finance.yahoo.com
NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer
February 29, 2024 | markets.businessinsider.com
NeuroBo Receives First Site IRB Approval For DA-1726 Obesity Trial; Stock Gains
February 29, 2024 | prnewswire.com
NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
February 12, 2024 | finance.yahoo.com
NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference
February 6, 2024 | finance.yahoo.com
NRBO: Initiating Coverage of NeuroBo Pharmaceuticals, Inc.; Targeting the $30 Billion+ Obesity Market…
February 2, 2024 | msn.com
NeuroBo’s DA-1726 Obesity Therapy Gets FDA IND Approval
February 1, 2024 | msn.com
Why Obesity-Drug Maker NeuroBo Stock Is Trading Higher
February 1, 2024 | markets.businessinsider.com
NeuroBo Pharma'a IND Application For DA-1726 Gets FDA Clearance
February 1, 2024 | markets.businessinsider.com
NeuroBo Rises 48% On Receiving FDA Approval For IND Application For DA-1726
February 1, 2024 | msn.com
NeuroBo to begin Phase 1 testing of potential Wegovy rival
February 1, 2024 | finance.yahoo.com
NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
January 30, 2024 | investing.com
Neurobo Pharmaceuticals Inc (NRBO)
January 18, 2024 | markets.businessinsider.com
NeuroBo Announces Positive Pre-Clinical Safety Data Of DA-1241 In Combination With Sitagliptin
January 18, 2024 | finance.yahoo.com
NRBO: Initiating Coverage of NeuroBo Pharmaceuticals, Inc.; Targeting the $30 Billion+ Obesity Market…
See More Headlines
Receive NRBO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroBo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
4/18/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NRBO
CUSIP
N/A
CIK
1638287
Web
www.neurobopharma.com
Phone
(857) 702-9600
Fax
734-293-0444
Employees
2
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-12,470,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-59.42%
Return on Assets
-45.40%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.78
Quick Ratio
3.78

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.44 per share
Price / Book
1.00

Miscellaneous

Outstanding Shares
4,910,000
Free Float
4,867,000
Market Cap
$16.94 million
Optionable
Not Optionable
Beta
-0.25
Metaverse Stocks And Why You Can't Ignore Them Cover
Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Hyung-Heon Kim (Age 49)
    CEO, President, Principal Executive & Director
    Comp: $54.22k
  • Mr. Marshall H. Woodworth (Age 66)
    CFO, Principal Financial Officer & Principal Accounting Officer
  • Dr. Mi-Kyung Kim
    Chief Scientific Officer
  • Mr. Robert Homolka
    Senior Vice President of Clinical Operations

Key Competitors

View All Competitors

NRBO Stock Analysis - Frequently Asked Questions

How have NRBO shares performed in 2024?

NeuroBo Pharmaceuticals' stock was trading at $3.70 at the beginning of 2024. Since then, NRBO shares have decreased by 8.1% and is now trading at $3.40.
View the best growth stocks for 2024 here.

When is NeuroBo Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our NRBO earnings forecast.

How were NeuroBo Pharmaceuticals' earnings last quarter?

NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) announced its earnings results on Monday, November, 15th. The company reported ($38.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($43.20) by $4.80.

When did NeuroBo Pharmaceuticals' stock split?

NeuroBo Pharmaceuticals shares reverse split before market open on Thursday, December 21st 2023. The 1-8 reverse split was announced on Thursday, December 21st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

What other stocks do shareholders of NeuroBo Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeuroBo Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), Cumberland Pharmaceuticals (CPIX), Akero Therapeutics (AKRO), Chimerix (CMRX), Trevena (TRVN), VBI Vaccines (VBIV), VIVUS (VVUS) and Aldeyra Therapeutics (ALDX).

How do I buy shares of NeuroBo Pharmaceuticals?

Shares of NRBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NRBO) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Priority Gold
[Urgent!] Generational Wealth Gameplan
Crypto 101 Media
Emergency: Biden's $20 Trillion Mistake Could Cost YOU!
GoldenCrest Metals
Biden’s $374B Giveaway Into This Sector
DTI
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
He Is Giving Away Bitcoin
Crypto Swap Profits